129 related articles for article (PubMed ID: 16287786)
41. Seroepidemiology and control of genital herpes: the value of type specific antibodies to herpes simplex virus.
Slomka MJ
Commun Dis Rep CDR Rev; 1996 Mar; 6(3):R41-5. PubMed ID: 8820192
[TBL] [Abstract][Full Text] [Related]
42. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
Bettahi I; Zhang X; Afifi RE; BenMohamed L
Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
[TBL] [Abstract][Full Text] [Related]
43. Interrupting herpes simplex virus type 2 transmission: the role of condoms and microbicides.
Langenberg A
Herpes; 2004 Aug; 11 Suppl 3():147A-154A. PubMed ID: 15319084
[TBL] [Abstract][Full Text] [Related]
44. Commentary on "HSV-1 and HSV-2 seroprevalence in the United States among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women)".
Burton MJ
South Med J; 2014 Feb; 107(2):85-6. PubMed ID: 24926672
[No Abstract] [Full Text] [Related]
45. Genital herpes.
Jungmann E
Clin Evid; 2004 Jun; (11):2073-88. PubMed ID: 15652098
[No Abstract] [Full Text] [Related]
46. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
47. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors.
Krone MR; Wald A; Tabet SR; Paradise M; Corey L; Celum CL
Clin Infect Dis; 2000 Feb; 30(2):261-7. PubMed ID: 10671325
[TBL] [Abstract][Full Text] [Related]
48. [Genital herpes].
Tewald F; Enders M; Regnath T; Hassler D
Dtsch Med Wochenschr; 2006 Nov; 131(47):2641-2. PubMed ID: 17190019
[No Abstract] [Full Text] [Related]
49. The potential epidemiological impact of a genital herpes vaccine for women.
Garnett GP; Dubin G; Slaoui M; Darcis T
Sex Transm Infect; 2004 Feb; 80(1):24-9. PubMed ID: 14755031
[TBL] [Abstract][Full Text] [Related]
50. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
51. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
[TBL] [Abstract][Full Text] [Related]
52. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
[TBL] [Abstract][Full Text] [Related]
53. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission.
Mertz GJ
J Infect Dis; 2008 Oct; 198(8):1098-100. PubMed ID: 18783317
[No Abstract] [Full Text] [Related]
54. [Treatment of genital herpes].
Hiltunen-Back E
Duodecim; 2001; 117(11):1175-9; quiz 1180, 1205. PubMed ID: 12116718
[No Abstract] [Full Text] [Related]
55. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada.
Romanowski B; Myziuk LN; Walmsley SL; Trottier S; Singh AE; Houston S; Joffe M; Chiu I
Sex Transm Dis; 2009 Mar; 36(3):165-9. PubMed ID: 19098690
[TBL] [Abstract][Full Text] [Related]
56. Patient and partner perceptions about preventing genital herpes transmission.
Gilbert L; Scanlon K; Peterson R; Ebel C
Herpes; 2005 Dec; 12(3):60-5. PubMed ID: 16393521
[TBL] [Abstract][Full Text] [Related]
57. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG
Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955
[TBL] [Abstract][Full Text] [Related]
58. Herpes simplex virus: who should be tested?
Malkin JE
Herpes; 2002 Jul; 9(2):31. PubMed ID: 12106507
[No Abstract] [Full Text] [Related]
59. Behavioral interventions for improving condom use for dual protection.
Lopez LM; Otterness C; Chen M; Steiner M; Gallo MF
Cochrane Database Syst Rev; 2013 Oct; (10):CD010662. PubMed ID: 24163112
[TBL] [Abstract][Full Text] [Related]
60. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.
Casanova G; Cancela R; Alonzo L; Benuto R; Magana Mdel C; Hurley DR; Fishbein E; Lara C; Gonzalez T; Ponce R; Burnett JW; Calton GJ
Cutis; 2002 Oct; 70(4):235-9. PubMed ID: 12403316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
